本帖最后由 老马 于 2012-1-13 21:20 编辑
- ?3 O" z" J8 A7 I* U$ N
5 }8 ?' J$ y0 a& [2 n爱必妥和阿瓦斯丁的比较
( z3 \' O0 E1 y; G9 K* C( @
4 }8 @9 H& J6 x9 h& |6 bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/" q) q( [% x5 t, l! C
1 b3 \7 E. [( [ E- V8 a* j- d
7 g+ j; D2 o& ^; x
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
y/ ? c& \" Z==================================================
* ^$ f% _& w0 e& I9 O/ g: iOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)+ i9 L* B& W$ M" @
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.3 S/ N/ B0 S' @4 w6 ~. C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 _% V# b; s4 {) ?7 `
|